Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) [Coronary Interventions]

Conclusions— Acquired thrombocytopenia after PCI is strongly associated with substantial early morbidity and mortality, as well as major bleeding. GPI use is a significant predictor of thrombocytopenia. Cangrelor is not associated with acquired thrombocytopenia, and its clinical efficacy and safety is consistent irrespective of thrombocytopenia occurrence. Clinical Trial Registration— URL: https://www.clinicaltrials.gov. Unique identifiers: NCT00305162, NCT00385138, and NCT01156571.

http://circinterventions.ahajournals.org/cgi/content/short/11/4/e005635?rss=1

Source: Circulation: Cardiovascular Interventions - April 9, 2018 Category: Cardiology Authors: Groves, E. M., Bhatt, D. L., Steg, P. G., Deliargyris, E. N., Stone, G. W., Gibson, C. M., Hamm, C. W., Mahaffey, K. W., White, H. D., Angiolillo, D., Prats, J., Harrington, R. A., Price, M. J., on behalf of the CHAMPION Investigators Tags: Platelets, Catheter-Based Coronary and Valvular Interventions, Percutaneous Coronary Intervention, Stent Coronary Interventions Source Type: research